Generic drug giant Mylan should beef up a compensation policy that requires top executives to give back incentive pay in the case of misconduct, according to a shareholder proposal submitted for the company’s upcoming annual meeting.
Mylan says shareholders will not be able to vote on the proposal because the pension plan that submitted it — the UAW Retiree Medical Benefits Trust in Detroit — doesn’t meet the submission criteria of owning at least 3 percent of Mylan’s shares.
Nonetheless, the drug company is asking shareholders to share their opinions on the matter, either in person at the annual meeting or via proxy cards being distributed for the meeting.
The annual meeting is set for June 21 in Amsterdam, the Netherlands, where Mylan reincorporated in 2015 to cut its U.S. tax bill. The company continues to be run from executive offices in Cecil.
Mylan plans to discuss the proposal at the annual meeting, but believes the proposed changes are “unnecessary at this time,” the company said in its proxy statement being mailed to shareholders.
So-called clawback policies are used by companies to recover compensation from senior executives in the event of fraud, malfeasance and/or a material financial restatement.
Read More
“Mylan currently has a robust clawback policy in place that is applicable to all executives,” the company said in its proxy statement.
The UAW pension fund — which owns 82,469 Mylan shares, or 0.16 percent of outstanding shares — said the company’s clawback policy isn’t broad enough.
The policy only allows recoupment of incentive pay resulting from misconduct that causes a financial restatement, the UAW fund said. “In our view, significant damage can be caused by misconduct that does not necessitate a financial restatement.”
In addition, it said, “It may be appropriate to hold accountable a senior executive who did not commit misconduct but … who failed to monitor or manage risks related to the misconduct.”
Under the proposal, the board’s compensation committee would have the authority to determine whether to seek reimbursement of incentive pay.
“In recent years, Mylan has faced regulatory actions related to misconduct in the marketing and sales of prescription drugs,” the UAW fund said.
It noted Mylan’s $465 million settlement with the U.S. Justice Department in 2017 for overcharging Medicaid millions of dollars for the EpiPen emergency allergy shot and allegations in a multistate lawsuit accusing Mylan and other drugmakers of conspiring to fix generic drug prices.
Strong clawback provisions are a powerful way to hold management accountable, the UAW fund said.
Patricia Sabatini: PSabatini@post-gazette.com; 412-263-3066.





Comments
Welcome to Post-Gazette subscriber-only commenting community. Please review our community guidelines.